AAAAAA
Results:
1-16
|
Results: 16
Authors:
Mazurier, C
Goudemand, J
Hilbert, L
Caron, C
Fressinaud, E
Meyer, D
Citation: C. Mazurier et al., Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology, BEST P R C, 14(2), 2001, pp. 337-347
Authors:
Beurton, I
Bertrand, MA
Bresson-Hadni, S
Parquet-Gernez, A
Goudemand, J
Paris, JC
Cales, P
Briquel, ME
Gaucher, P
Cortey, ML
Trepo, C
Miguet, JP
Cahn, JY
Citation: I. Beurton et al., Interferon alpha therapy in haemophilic patients with chronic hepatitis C:a French multicentre pilot study of 58 patients, EUR J GASTR, 13(7), 2001, pp. 859-864
Authors:
Levesque, H
Borg, JY
Bossi, P
Goudemand, J
Guillet, B
Cabane, J
Citation: H. Levesque et al., Acquired haemophilia: diagnosis and therapeutic management., REV MED IN, 22(9), 2001, pp. 854-866
Authors:
Giansily-Blaizot, M
Aguilar-Martinez, P
Mazurier, C
Cneude, F
Goudemand, J
Schved, JF
de Martinville, B
Citation: M. Giansily-blaizot et al., Prenatal diagnosis of severe factor VII deficiency using mutation detection and linkage analysis, BR J HAEM, 112(1), 2001, pp. 251-252
Authors:
Christophe, OD
Lenting, PJ
Cherel, G
Boon-Spijker, M
Lavergne, JM
Boertjes, R
Briquel, ME
de Goede-Bolder, A
Goudemand, J
Gaillard, S
d'Oiron, R
Meyer, D
Mertens, K
Citation: Od. Christophe et al., Functional mapping of anti-factor IX inhibitors developed in patients withsevere hemophilia B, BLOOD, 98(5), 2001, pp. 1416-1423
Authors:
Ribba, AS
Hilbert, L
Lavergne, JM
Fressinaud, E
Boyer-Neumann, C
Ternisien, C
Juhan-Vague, I
Goudemand, J
Girma, JP
Mazurier, C
Meyer, D
Citation: As. Ribba et al., The arginine-552-cysteine (R1315C) mutation within the Al loop of von Willebrand factor induces an abnormal folding with a loss of function resultingin type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor, BLOOD, 97(4), 2001, pp. 952-959
Authors:
Wibaut, B
Vannier, V
Renom, P
Goudemand, J
Citation: B. Wibaut et al., Platelet transfusion and allergic transfusion reactions: Lille Hospital's experience over a four-year period., TRANSF CL B, 7(2), 2000, pp. 177-185
Authors:
Jorieux, S
Fressinaud, E
Goudemand, J
Gaucher, C
Meyer, D
Mazurier, C
Citation: S. Jorieux et al., Conformational changes in the D ' domain of von Willebrand factor induced by CYS 25 and CYS 95 mutations lead to factor VIII binding defect and multimeric impairment, BLOOD, 95(10), 2000, pp. 3139-3145
Authors:
Goudemand, J
Citation: J. Goudemand, Treatment of patients with inhibitors: cost issues, HAEMOPHILIA, 5(6), 1999, pp. 397-401
Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors
Authors:
Batlle, J
Lopez, MF
Brackmann, HH
Gaillard, S
Goudemand, J
Humbert, J
De Moerloose, P
Maass, E
Mauz-Korholz, C
Sultan, Y
Stieltjes, N
Citation: J. Batlle et al., Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors, HAEMOPHILIA, 5(6), 1999, pp. 431-435
Authors:
Renom, P
Wibaut, B
Savage, C
Vannier, V
Goudemand, J
Citation: P. Renom et al., Diagnosis complexities of transfusion-related bacterial sepsis: two cases., TRANSF CL B, 6(2), 1999, pp. 124-128
Authors:
Siaka, C
Lambert, M
Caron, C
Amiral, J
Hachulla, E
Hatron, PY
Goudemand, J
Citation: C. Siaka et al., Low prevalence of anti-annexin V antibodies in anti-phospholipid syndrome accompanied by spontaneous abortion., REV MED IN, 20(9), 1999, pp. 762-765
Authors:
Goudemand, J
Negrier, C
Ounnoughene, N
Sultan, Y
Citation: J. Goudemand et al., Clinical management of patients with von Willebrand's disease with a VHP vWF concentrate: the French experience, HAEMOPHILIA, 4, 1998, pp. 48-52
Authors:
Goudemand, J
Citation: J. Goudemand, Pharmaco-economic aspects of inhibitor treatment, EUR J HAEMA, 61, 1998, pp. 24-27
Authors:
Goudemand, J
Peynet, J
Chambost, H
Negrier, C
Briquel, ME
Claeyssens, S
Derlon-Borel, A
Guerois, C
Caron, C
Scherrmann, JM
Debray, M
Bridey, F
Citation: J. Goudemand et al., A cross-over pharmacokinetic study of a double viral inactivated factor IXconcentrate (15 nm filtration and SD) compared to a SD factor IX concentrate, THROMB HAEM, 80(6), 1998, pp. 919-924
Authors:
Jorieux, S
Gaucher, C
Goudemand, J
Mazurier, C
Citation: S. Jorieux et al., A novel mutation in the D3 domain of von Willebrand factor markedly decreases its ability to bind factor VIII and affects its multimerization, BLOOD, 92(12), 1998, pp. 4663-4670
Risultati:
1-16
|